In an intention-to-treat analysis , the twelve month cumulative rates of confirmed CMV disease were 26 percent in the placebo group ( n = 239 ) and 14 percent in the ganciclovir group ( n = 486 ) , representing an overall reduction in risk of 49 percent in the ganciclovir group ( P < 0.001 ) .
